Literature DB >> 1836919

Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy.

G Giammanco1, S Li Volti, L Mauro, G G Bilancia, I Salemi, P Barone, S Musumeci.   

Abstract

The reactogenicity and immunogenicity of simultaneous administration of recombinant DNA hepatitis B vaccine with diphtheria and tetanus toxoids (DT) and oral poliovirus vaccine (OPV) in 111 infants were compared with those of DT and OPV alone in a control group of 21 infants. All subjects received three doses of the vaccine according to one of three different schedules of vaccination. Reactions following simultaneous administration of vaccines were all but absent, with mild pain reported for four out of 111 subjects, compared with one of 21 in the control group. Seroconversion rates of 98-100% and high anti-HBs geometric mean titres (GMTs) were observed in all study groups after three doses of hepatitis B vaccine. Significantly higher anti-HBs were seen in Group III, where six months is allowed between the second and the third hepatitis B vaccine doses, compared with Group I and II, where only 1-2 months separate the second and third doses. A fourth dose of vaccine was needed in both these groups to obtain anti-HBs levels as high as seen in Group III after three vaccine doses at 3, 4 and 10 months of age. The immune response to DT and OPV was similar in the study groups and the control group. It is concluded that a course of 10 micrograms doses of recombinant hepatitis B vaccine given simultaneously with DT and OPV elicits a strong anti-HBs response and does not interfere with the immune response to the other antigens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1836919     DOI: 10.1016/0264-410x(91)90291-d

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Duration of hepatitis B antibody response in children immunised with hepatitis B and compulsory vaccines.

Authors:  S Li Volti; G Giammanco-Bilancia; G Giammanco; F Mollica
Journal:  Eur J Epidemiol       Date:  1995-04       Impact factor: 8.082

2.  Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth.

Authors:  N Linder; R Handsher; B German; L Sirota; M Bachman; S Zinger; E Mendelson; A Barzilai
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-07       Impact factor: 5.747

3.  Hepatitis B vaccine in the EPI schedule.

Authors:  Ajay Kumar Jain; S K Mittal; S Ramji; A Chakravarti
Journal:  Indian J Pediatr       Date:  2005-08       Impact factor: 1.967

4.  Evaluation of potentially achievable vaccination coverage of the second dose of measles containing vaccine with simultaneous administration and risk factors for missed opportunities among children in Zhejiang province, east China.

Authors:  Yu Hu; Yaping Chen; Ying Wang; Hui Liang
Journal:  Hum Vaccin Immunother       Date:  2018-01-23       Impact factor: 3.452

5.  Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines.

Authors: 
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

6.  Hepatitis B Vaccine Coverage and the Immune Response in Children under ten years old in Sana'a, Yemen.

Authors:  Hassan A Al-Shamahy; Samira H Hanash; Iqbal A Rabbad; Nameem M Al-Madhaji; Samarih M Naser
Journal:  Sultan Qaboos Univ Med J       Date:  2011-02-12

Review 7.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Hepatitis B vaccine development and implementation.

Authors:  Hong Zhao; Xiaoying Zhou; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

Review 9.  Vaccines for immunoprevention of cancer.

Authors:  Tomohiro Enokida; Alvaro Moreira; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

10.  Immune thrombocytopenic purpura risk by live, inactivated and simultaneous vaccinations among Japanese adults, children and infants: a matched case-control study.

Authors:  Hiroshi Yokomichi; Keiko Tanaka-Taya; Rie Koshida; Takashi Nakano; Yoshinori Yasui; Masaaki Mori; Yuka Ando; Saeko Morino; Hideo Okuno; Hiroshi Satoh; Satoru Arai; Mie Mochizuki; Zentaro Yamagata
Journal:  Int J Hematol       Date:  2020-04-06       Impact factor: 2.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.